Search by Drug Name or NDC
NDC 62856-0389-01 Halaven 0.5 mg/mL Details
Halaven 0.5 mg/mL
Halaven is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eisai Inc.. The primary component is ERIBULIN MESYLATE.
MedlinePlus Drug Summary
Eribulin injection is used to treat breast cancer that has spread to other parts of the body and that has already been treated with certain other chemotherapy medications. Eribulin is in a class of anticancer medications called microtubule dynamics inhibitors. It works by stopping the growth and spread of cancer cells.
Related Packages: 62856-0389-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Eribulin Injection
Product Information
| NDC | 62856-0389 |
|---|---|
| Product ID | 62856-389_e3f88313-4de7-40ce-94b3-a848e4367037 |
| Associated GPIs | 21500009202020 |
| GCN Sequence Number | 066838 |
| GCN Sequence Number Description | eribulin mesylate VIAL 1 MG/2 ML INTRAVEN |
| HIC3 | V3I |
| HIC3 Description | ANTINEOPLASTIC - MICROTUBULE INHIBITORS |
| GCN | 29249 |
| HICL Sequence Number | 037256 |
| HICL Sequence Number Description | ERIBULIN MESYLATE |
| Brand/Generic | Brand |
| Proprietary Name | Halaven |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | eribulin mesylate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 0.5 |
| Active Ingredient Units | mg/mL |
| Substance Name | ERIBULIN MESYLATE |
| Labeler Name | Eisai Inc. |
| Pharmaceutical Class | Microtubule Inhibition [PE], Microtubule Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA201532 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 62856-0389-01 (62856038901)
| NDC Package Code | 62856-389-01 |
|---|---|
| Billing NDC | 62856038901 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (62856-389-01) / 2 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2010-11-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |